Navigation Links
PAREXEL Receives BioSingapore Award for Best Performing CRO
Date:3/23/2009

pects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
2. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
3. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
4. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
5. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
6. PAREXEL Receives Best CRO Award from Scrip
7. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
8. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
9. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
10. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
11. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)...  China Cord Blood Corporation (NYSE: CO ... financial results for the first quarter of fiscal year ... in the US.  The Company will ... Friday, August 29, 2014 to discuss its financial performance ... developments, followed by a question and answer session.  Interested ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Ontotext ... today by Ontotext . Now the same ... analysis of structured and unstructured data is available to ... cost of enterprise technology. Organizations that do not have ... data management can use S4 since there is no ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... , SEATTLE, Dec. 6 A challenge donation from the ... total to more than $7 million for Fred Hutchinson Cancer Research ... during which guests raise their bid cards for specific contribution levels, ... work to harness the human immune system to battle cancer. ...
... , NEW YORK, Dec. 4 Stemline Therapeutics, Inc. ... agents, SL-401 and SL-501, in both in vitro and ... for poster presentation at the upcoming 51st Annual Meeting of the ... from December 5-8, 2009. The poster will be presented by Stemline,s ...
... Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... the treatment of cardiovascular and metabolic disease, today announced that ... 2 FDG-PET clinical trial of VIA-2291. , The FDG-PET ... sites in the US and Canada including Massachusetts General Hospital, ...
Cached Biology Technology:34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
(Date:8/22/2014)... to purchase fuel cell cars from Toyota and other ... cars will run on hydrogen made from natural gas, ... Now scientists at Stanford University have developed a low-cost, ... produce hydrogen by water electrolysis. The battery sends ... water into hydrogen and oxygen gas. Unlike other water ...
(Date:8/21/2014)... BLOOMINGTON, Ind. -- A new study of American ... partner, men have the highest orgasm rates. On ... time, with their sexual orientation making little difference. ... On average, women experience orgasm 62.9 percent of ... -- and this pattern varies with women,s sexual ...
(Date:8/21/2014)... to dandruff, eczema and other itchy, flaky maladies in ... reachesincluding Hawaiian coral reefs and the extreme environments of ... in the scientific journal PLOS Pathogens considers ... the genus Malassezia in light of new ... the world. , University of Hawai,i at Mānoa scientist ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... Athene Donald has won the Science and Technology award ... honor to Professor Donald, Glamour magazine praised her as a ... real path for herself in the male-dominated world of physics." ... Physics at the University of Cambridge in the United Kingdom ...
... CAA researcher at Charles Drew University of Medicine and Science ... a promising, natural therapy for cancer. Dr. Mamdooh Ghoneum ... on "Cell Death Mechanism," sponsored by the American Association for ... San Diego. "The central focus of the meeting ...
... RIVERSIDE, Calif. Stem cell research at the University of ... establishment of a new Stem Cell Core Facility (SCCF) ... doing stem cell research that ordinarily would not be available ... Noel Keen Hall, had its grand opening on Friday, Jan. ...
Cached Biology News:Charles Drew cancer studies with yeast yield excellent results 2UC Riverside's new state-of-the-art technology to accelerate stem cell research 2
... offers a full length insert sequencing service ... cosmids and fosmids. Agencourt utilizes unique ... libraries. There are several features that ... data with rapid turnaround including our patented ...
...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
A flexible 24-48 hour DNA sequencing service. Samples may be shipped in standard 1.5mL tubes. Oligo synthesis and DNA preparation available. Read lengths up to 850 Phred 20 bases. Universal primers p...
Biology Products: